Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30133444 | 1.00 | HTR2A (0.43) | HTR2AHTR2CCA1CA2CA7 | |
| SCHEMBL7802337 | 0.87 | CA1 (0.50) | HTR2AHTR2CCA1CA2CA7 | |
| SCHEMBL23499986 | 0.85 | CA1 (0.44) | HTR2AHTR2CCA1CA2CA7 | |
| SCHEMBL8342978 | 0.83 | HTR2A (0.43) | HTR2AHTR2CCA1CA2CA7 | |
| SCHEMBL27797008 | 0.82 | HTR2A (0.42) | HTR2AHTR2CCA1CA2CA7 | |
| SCHEMBL14879898 | 0.82 | MAPT (0.42) | HTR2AHTR2CCA1CA2CA7 | |
| SCHEMBL21768194 | 0.82 | HTR2A (0.42) | HTR2AHTR2CCA1CA2CA7 | |
| SCHEMBL2061829 | 0.81 | NQO2 (0.39) | HTR2AHTR2CCA2SMN1; SMN2MAPT | |
| SCHEMBL19412338 | 0.80 | ALDH1A1 (0.42) | SMN1; SMN2MAPTHPGDL3MBTL1CYP1A2 | |
| SCHEMBL695730 | 0.79 | CA1 (0.42) | HTR2AHTR2CCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4126843-B1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12441743-B2 | Spiro aromatic ring compound and use thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2025-10-14 | — | — | US | disclosed |
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORP (US) | 2025-09-11 | — | — | US | disclosed |
| CN-111566104-B | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20240116949-A1 | SPIRO AROMATIC RING COMPOUND AND USE THEREOF | ETERN BIOPHARMA SHANGHAI CO LTD (CN) | 2024-04-11 | — | — | US | disclosed |
| CN-117143079-A | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| CN-111138412-B | Spiro aromatic ring compound and application thereof | 上海奕拓医药科技有限责任公司 | 2023-09-15 | — | — | CN | disclosed |
| EP-4227307-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | Genzyme Corporation (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3204359-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2017-08-16 | — | — | EP | disclosed |
| CN-107001278-A | Tetrahydro isoquinoline derivative | UCB生物制药私人有限公司 | 2017-08-01 | — | — | CN | disclosed |
| WO-2016055479-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055479-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
| US-20130150350-A1 | Derivatives of 1-Phenyl-1,5-Dihydro-Benzo[B] [1,4]Diazepine-2,4-Dione as Inhibitors of HIV Replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150350-A1 | Derivatives of 1-Phenyl-1,5-Dihydro-Benzo[B] [1,4]Diazepine-2,4-Dione as Inhibitors of HIV Replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| WO-2011100838-A1 | DERIVATIVES OF 1-PHENYL-1,5-DIHYDRO-BENZO[B] [1.4]DIAZEPINE-2.4-DIONE AS INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
| EP-1236717-B1 | OXIME O-ETHER COMPOUNDS AND FUNGICIDES FOR AGRICULTURAL AND HORTICULTURAL USE | NIPPON SODA CO (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-6589967-B1 | Fungicide for agricultural and horticultural use comprising the compound as the active ingredient. agricultural plant protection chemicals have been used for controlling plant diseases. | NIPPON SODA CO. LTD. (JP) | 2003-07-08 | — | — | US | disclosed |
| EP-1236717-A1 | OXIME O-ETHER COMPOUNDS AND FUNGICIDES FOR AGRICULTURAL AND HORTICULTURAL USE | NIPPON SODA CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150350-A1 | Derivatives of 1-Phenyl-1,5-Dihydro-Benzo[B] [1,4]Diazepine-2,4-Dione as Inhibitors of HIV Replication | MED1, ZC3HAV1, BET1 | HTR2A 2604/4885HTR2C 2560/4885CA1 4833/4885 |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | HTR2A 2984/4885HTR2C 2063/4885CA1 2213/4885 |
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | PTPN5, PTPN2, PTPRJ | HTR2A 3451/4885HTR2C 3250/4885CA1 4481/4885 |
| US-20240116949-A1 | SPIRO AROMATIC RING COMPOUND AND USE THEREOF | PTPN1, PTPN11, PTPN5 | HTR2A 4186/4885HTR2C 3401/4885CA1 2261/4885 |
| US-12441743-B2 | Spiro aromatic ring compound and use thereof | PTPN1, PTPN11, PTPN5 | HTR2A 4186/4885HTR2C 3401/4885CA1 2261/4885 |
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | NR3C1, NR2C2, RIOX2 | HTR2A 1501/4885HTR2C 544/4885CA1 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.